NASDAQ:ZYXI - Zynex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.63
  • Forecasted Upside: 44.07 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$15.01
▼ -0.35 (-2.28%)
1 month | 3 months | 12 months
Get New Zynex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYXI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$21.63
▲ +44.07% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Zynex in the last 3 months. The average price target is $21.63, with a high forecast of $25.00 and a low forecast of $19.00. The average price target represents a 44.07% upside from the last price of $15.01.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Zynex. This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/20/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/18/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/17/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021Northland SecuritiesUpgradeMarket Perform ➝ OutperformN/A
i
3/9/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$22.50High
i
2/26/2021B. RileyDowngradeBuy ➝ Neutral$19.00High
i
Rating by M. Wiesenberger at B. Riley
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$28.00 ➝ $20.00High
i
1/28/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$22.50High
i
10/28/2020Northland SecuritiesReiterated RatingBuy$22.50High
i
Rating by James Terwilliger at Northland Securities
9/14/2020HC WainwrightUpgradeNeutral ➝ BuyMedium
i
Rating by Y. Chen at HC Wainwright
9/9/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$22.50Medium
i
Rating by James Terwilliger at Northland Securities
7/29/2020B. RileyUpgradeNeutral ➝ Buy$28.00Medium
i
Rating by M. Wiesenberger at B. Riley
7/29/2020Northland SecuritiesReiterated RatingHold$22.50High
i
Rating by James Terwilliger at Northland Securities
7/29/2020HC WainwrightLower Price TargetNeutral$30.00 ➝ $25.00High
i
Rating by Yi Chen at HC Wainwright
7/20/2020Piper SandlerInitiated CoverageOverweight$30.00Medium
i
7/13/2020B. RileyDowngradeBuy ➝ NeutralLow
i
Rating by M. Wiesenberger at B. Riley
7/10/2020HC WainwrightReiterated RatingNeutral$20.00 ➝ $30.00High
i
Rating by Yi Chen at HC Wainwright
6/16/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$21.00High
i
Rating by James Terwilliger at Northland Securities
5/29/2020B. RileyBoost Price TargetBuy$18.50 ➝ $25.50High
i
Rating by Marc Wiesenberger at B. Riley
5/19/2020Northland SecuritiesReiterated RatingBuy$21.00Low
i
5/19/2020HC WainwrightDowngradeBuy ➝ Neutral$20.00Low
i
Rating by Yi Chen at HC Wainwright
4/29/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $20.00High
i
Rating by Yi Chen at HC Wainwright
4/8/2020HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Yi Chen at HC Wainwright
4/1/2020Northland SecuritiesInitiated CoverageOutperform$15.00Low
i
3/30/2020B. RileyLower Price TargetBuy$20.50 ➝ $18.50High
i
Rating by Marc Wiesenberger at B. Riley
2/26/2020HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Yi Chen at HC Wainwright
2/21/2020B. RileyBoost Price TargetBuy$12.00 ➝ $19.75High
i
Rating by Marc Wiesenberger at B. Riley
2/4/2020HC WainwrightReiterated RatingBuy$12.00Low
i
Rating by Yi Chen at HC Wainwright
1/10/2020HC WainwrightReiterated RatingBuy$12.00Low
i
Rating by Yi Chen at HC Wainwright
1/9/2020B. RileyReiterated RatingBuy$12.00Low
i
Rating by Marc Wiesenberger at B. Riley
10/30/2019HC WainwrightReiterated RatingBuy$12.00High
i
10/22/2019B. RileyBoost Price TargetBuy$10.75 ➝ $12.00High
i
10/15/2019B. RileyReiterated RatingBuyLow
i
Rating by M. Wiesenberger at B. Riley
9/23/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Y. Chen at HC Wainwright
9/23/2019HC WainwrightInitiated CoverageBuy$12.00High
i
8/2/2019B. RileyBoost Price TargetBuy$9.00 ➝ $10.75Medium
i
Rating by Marc Wiesenberger at B. Riley
2/22/2019B. RileyReiterated RatingBuyHigh
i
Rating by Marc Wiesenberger at B. Riley
11/2/2018B. RileySet Price TargetBuy$7.00Low
i
Rating by Marc Wiesenberger at B. Riley
10/10/2018B. RileyInitiated CoverageBuy$7.00Medium
i
Rating by M. Wiesenberger at B. Riley
8/21/2017Taglich BrothersReiterated RatingSpeculative BuyN/A
i
Rating by H. Halpern at Taglich Brothers
(Data available from 6/16/2016 forward)
Zynex logo
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Read More

Today's Range

Now: $15.01
$14.92
$15.50

50 Day Range

MA: $15.10
$13.48
$16.36

52 Week Range

Now: $15.01
$12.53
$29.73

Volume

162,968 shs

Average Volume

475,767 shs

Market Capitalization

$523.05 million

P/E Ratio

93.82

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Zynex?

The following sell-side analysts have issued stock ratings on Zynex in the last twelve months: B. Riley, HC Wainwright, Northland Securities, Piper Sandler, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ZYXI.

What is the current price target for Zynex?

4 Wall Street analysts have set twelve-month price targets for Zynex in the last year. Their average twelve-month price target is $21.63, suggesting a possible upside of 44.1%. HC Wainwright has the highest price target set, predicting ZYXI will reach $25.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $19.00 for Zynex in the next year.
View the latest price targets for ZYXI.

What is the current consensus analyst rating for Zynex?

Zynex currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYXI will outperform the market and that investors should add to their positions of Zynex.
View the latest ratings for ZYXI.

What other companies compete with Zynex?

How do I contact Zynex's investor relations team?

Zynex's physical mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company's listed phone number is 303 703 4906 and its investor relations email address is [email protected] The official website for Zynex is www.zynex.com.